3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis. J of Skin [Internet]. 2023 Mar. 13 [cited 2026 Apr. 20];7(2):s142. Available from: https://skin.dermsquared.com/skin/article/view/2028